PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Commentary|Podcasts|July 11, 2024
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
Author(s)Brooke McCormick
On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Advertisement
On this episode of Managed Care Cast, we're talking with Sreekanth Chaguturu, MD, the chief medical officer of CVS Health.
We discuss the impact of recent pharmaceutical innovations, namely
Listen above or on one of these podcast services:
Advertisement
Related to this article
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Machine Learning Has High Accuracy, Little Prospective Validation in MPNs
3
The Next Decade of Cancer Care Is Coming Home: Who Will Be in the Driver’s Seat?
4
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
5